Πλοήγηση ανά Συγγραφέα "Befani, C. D."
-
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner
Vlachostergios, P. J.; Hatzidaki, E.; Befani, C. D.; Liakos, P.; Papandreou, C. N. (2013)Development of drug resistance after standard chemotherapy for glioblastoma multiforme (GBM) with temozolomide (TMZ) is associated with poor prognosis of GBM patients and is at least partially mediated by a direct DNA ... -
Bortezomib represses HIF-1 alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
Befani, C. D.; Vlachostergios, P. J.; Hatzidaki, E.; Patrikidou, A.; Bonanou, S.; Simos, G.; Papandreou, C. N.; Liakos, P. (2012)Bortezomib represents the first proteasome inhibitor (PI) with demonstrated antitumor activity in the clinical setting, particularly for treatment of hematological malignancies. At the preclinical level, its action is shown ... -
Bortezomib represses HIF-1 alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells (vol 90, pg 45, 2012)
Befani, C. D.; Vlachostergios, P. J.; Hatzidaki, E.; Patrikidou, A.; Bonanou, S.; Simos, G.; Papandreou, C. N.; Liakos, P. (2013) -
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells
Tsapakidis, K.; Vlachostergios, P. J.; Voutsadakis, I. A.; Befani, C. D.; Patrikidou, A.; Hatzidaki, E.; Daliani, D. D.; Moutzouris, G.; Liakos, P.; Papandreou, C. N. (2012)Objectives: Neuropeptides are important signal initiators in advanced prostate cancer, partially acting through activation of nuclear factor kappa B. Central to nuclear factor kappa B regulation is the ubiquitin-proteasome ...